目的 分析辽宁省肿瘤医院2020—2022年单抗类靶向药物的使用情况以及变化趋势，为临床抗肿瘤药安全合理经济用药提供参考依据。方法 收集2020—2022年辽宁省肿瘤医院单抗类靶向药物使用数据，分析销售金额、用药频度（DDDs）、限定日费用（DDC）以及排序比（B/A）。结果 2020—2022年单抗类靶向药物销售金额逐年增长。贝伐珠单抗和曲妥珠单抗连续3年销售金额排名前2位。帕妥珠单抗由2020年的第5位增长到2022年的第3位。曲妥珠单抗DDDs连续3年均排在第1位。2022年新增品种（维迪西妥单抗、维布妥昔单抗、达雷妥尤单抗等）销售金额和DDDs排名均相对靠后，但其DDC值较高。地舒单抗、曲妥珠单抗、帕妥珠单抗、伊尼妥单抗等的DDC值较低，且B/A＞1，利妥昔单抗、贝伐珠单抗的B/A＜1。结论 2020—2022年辽宁省肿瘤医院单抗类靶向药物的结构总体上较为合理，能满足患者的医疗需求，保障患者用药的安全、有效和经济。

Objective To analyze the usage and variation tendency of monoclonal antibody targeting drugs in Liaoning Cancer Hospital & Institute from 2020 to 2022, and provide references for standardizing the management and rational application. Methods Consumption sum, DDDs, DDC, and drug sequence ratio of monoclonal antibody targeting drugs in Liaoning Cancer Hospital & Institute from 2020 to 2022 were analyzed statistically. Results From 2020 to 2022, the sales amount of monoclonal antibody targeting drugs increased year by year. Bevacizumab and trastuzumab ranked top 2 in consumption sum for 3 consecutive years. Pertuzumab increased from 5th place in 2020 to 3rd place in 2022. Trastuzumab DDDs ranked the first place for 3 consecutive years. The consumption sum and DDDs of the new varieties (disitamab vedotin, brentuximab vedotin, daratumumab, etc.) in 2022 were relatively lower, but their DDC value was higher. The DDC values of denosumab, trastuzumab, pertuzumab, and inetetamab were low, and the sequencing ratio was >1, while the sequencing ratio of rituximab and bevacizumab was < 1. Conclusion From 2020 to 2022, the use of monoclonal antibody targeting drugs in Liaoning Cancer Hospital & Institute is generally reasonable. It can meet the medical needs of patients and guarantee the safety, effectiveness and economy of medication for patients.

R979.1

辽宁省肿瘤医院质谱课题项目(ZP202019)